Compugen (CGEN) Competitors

CureVac (NASDAQ:CVAC) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation.

Does the MarketBeat Community believe in CVAC or CGEN?

Compugen received 283 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 64.38% of users gave Compugen an outperform vote while only 55.32% of users gave CureVac an outperform vote.

Company	Underperform	Outperform
CureVac	Outperform Votes 26 55.32%	Underperform Votes 21 44.68%
Compugen	Outperform Votes 309 64.38%	Underperform Votes 171 35.63%

Which has more volatility & risk, CVAC or CGEN?

CureVac has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of CVAC or CGEN?

17.3% of CureVac shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable earnings & valuation, CVAC or CGEN?

Compugen has higher revenue and earnings than CureVac. CureVac is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$58.18M	12.70	-$281.58M	$0.55	6.00
Compugen	$59.85M	3.14	-$18.75M	$0.02	105.30

Do analysts prefer CVAC or CGEN?

CureVac currently has a consensus price target of $10.00, indicating a potential upside of 203.03%. Compugen has a consensus price target of $4.00, indicating a potential upside of 89.93%. Given CureVac's higher probable upside, equities research analysts clearly believe CureVac is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Compugen	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is CVAC or CGEN more profitable?

CureVac has a net margin of 20.72% compared to Compugen's net margin of 2.67%. CureVac's return on equity of 21.98% beat Compugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	20.72%	21.98%	15.72%
Compugen	2.67%	2.62%	1.36%

Does the media favor CVAC or CGEN?

In the previous week, CureVac had 3 more articles in the media than Compugen. MarketBeat recorded 8 mentions for CureVac and 5 mentions for Compugen. Compugen's average media sentiment score of 0.55 beat CureVac's score of 0.52 indicating that Compugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CureVac	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compugen beats CureVac on 10 of the 18 factors compared between the two stocks.